Skip to content

Study · Animal study (in vivo) · mouse · 1990

10 results

Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice.

Gillespie C, Read LC, Bagley CJ, Ballard FJ

The Journal of endocrinology1 Dec 1990Cited by 16 (Europe PMC)

PMID2280209 (opens in a new tab)DOI10.1677/joe.0.1270401 (opens in a new tab)PepBankPUB-02280209
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, lower-dose des(1‑3)IGF-I increased total length more than controls or lower-dose IGF-I.

    In plain wordsIn mice, lower-dose des(1‑3)IGF-I increased total length more than controls or lower-dose IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseTotal length at lower dose
    Study

    mousen: not reported in source

    lit/lit mice
    Comparator
    Controls or IGF-I 3 micrograms daily
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    3 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
    1 context sentence
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, higher-dose des(1‑3)IGF-I increased total length more than controls or lower-dose IGF-I.

    In plain wordsIn mice, higher-dose des(1‑3)IGF-I increased total length more than controls or lower-dose IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseTotal length at higher dose
    Study

    mousen: not reported in source

    lit/lit mice
    Comparator
    Controls or IGF-I 3 micrograms daily
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
    1 context sentence
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, lower-dose des(1‑3)IGF-I increased nose-rump length more than controls or lower-dose IGF-I.

    In plain wordsIn mice, lower-dose des(1‑3)IGF-I increased nose-rump length more than controls or lower-dose IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseNose-rump length at lower dose
    Study

    mousen: not reported in source

    lit/lit mice
    Comparator
    Controls or IGF-I 3 micrograms daily
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    3 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
    1 context sentence
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, higher-dose des(1‑3)IGF-I increased nose-rump length more than controls or lower-dose IGF-I.

    In plain wordsIn mice, higher-dose des(1‑3)IGF-I increased nose-rump length more than controls or lower-dose IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseNose-rump length at higher dose
    Study

    mousen: not reported in source

    lit/lit mice
    Comparator
    Controls or IGF-I 3 micrograms daily
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
    1 context sentence
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, body weight changes with des(1‑3)IGF-I were not statistically significant.

    In plain wordsIn mice, des(1‑3)IGF-I did not significantly change body weight.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeBody weight
    Study

    mousen: not reported in source

    lit/lit mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Body weight changes were not statistically significant.
    2 context sentences
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
    Summary · context
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, lower-dose des(1‑3)IGF-I increased kidney weight relative to controls.

    In plain wordsIn mice, lower-dose des(1‑3)IGF-I increased kidney weight compared with controls.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseKidney weight at lower dose
    Study

    mousen: not reported in source

    lit/lit mice
    Comparator
    Controls
    Outcome group
    Body composition · Kidney and urinary
    Studied dose
    3 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The lower dose of des(1-3)IGF-I, but not that of IGF-I, led to increases in kidney and heart weights relative to controls, while the higher dose of either IGF-I or des(1-3)IGF-I also increased the weights of liver, lungs and stomach.
    2 context sentences
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
    Summary · context
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, lower-dose des(1‑3)IGF-I increased heart weight relative to controls.

    In plain wordsIn mice, lower-dose des(1‑3)IGF-I increased heart weight compared with controls.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseHeart weight at lower dose
    Study

    mousen: not reported in source

    lit/lit mice
    Comparator
    Controls
    Outcome group
    Body composition · Cardiovascular
    Studied dose
    3 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The lower dose of des(1-3)IGF-I, but not that of IGF-I, led to increases in kidney and heart weights relative to controls, while the higher dose of either IGF-I or des(1-3)IGF-I also increased the weights of liver, lungs and stomach.
    2 context sentences
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
    Summary · context
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, higher-dose des(1‑3)IGF-I increased liver weight.

    In plain wordsIn mice, higher-dose des(1‑3)IGF-I increased liver weight.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseLiver weight at higher dose
    Study

    mousen: not reported in source

    lit/lit mice
    Outcome group
    Body composition · Liver
    Studied dose
    30 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The lower dose of des(1-3)IGF-I, but not that of IGF-I, led to increases in kidney and heart weights relative to controls, while the higher dose of either IGF-I or des(1-3)IGF-I also increased the weights of liver, lungs and stomach.
    2 context sentences
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
    Summary · context
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, higher-dose des(1‑3)IGF-I increased lung weight.

    In plain wordsIn mice, higher-dose des(1‑3)IGF-I increased lung weight.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseLung weight at higher dose
    Study

    mousen: not reported in source

    lit/lit mice
    Outcome group
    Body composition · Respiratory
    Studied dose
    30 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The lower dose of des(1-3)IGF-I, but not that of IGF-I, led to increases in kidney and heart weights relative to controls, while the higher dose of either IGF-I or des(1-3)IGF-I also increased the weights of liver, lungs and stomach.
    2 context sentences
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
    Summary · context
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In lit/lit mice, higher-dose des(1‑3)IGF-I increased stomach weight.

    In plain wordsIn mice, higher-dose des(1‑3)IGF-I increased stomach weight.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseStomach weight at higher dose
    Study

    mousen: not reported in source

    lit/lit mice
    Outcome group
    Body composition · Gastrointestinal
    Studied dose
    30 micrograms daily · injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The lower dose of des(1-3)IGF-I, but not that of IGF-I, led to increases in kidney and heart weights relative to controls, while the higher dose of either IGF-I or des(1-3)IGF-I also increased the weights of liver, lungs and stomach.
    2 context sentences
    Summary · context
    The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice.
    Summary · context
    Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.